September 29, 2020
12:00 - 12:30 pm ET

As companies have adapted their operations to the realities of the COVID-19 pandemic, many have found themselves navigating U.S. drug and device law for the first time.  So far, this process has been significantly simplified by regulatory waivers and emergency use authorizations (EUA), but with the current public health emergency declaration scheduled to expire on October 23, 2020, now is the time to reassess your company’s FDA compliance.  Join us as we discuss where to start and what to consider in this complimentary half-hour webinar.



Jolie Havens

Jolie is a partner in the Vorys Columbus office and the chair of the firm’s health care industry group. Jolie maintains a national practice focused on health care compliance and provider/practitioner reimbursement, with significant experience involving hospitals and physicians. 


Mairi Mull

Mairi is an associate in the Vorys Pittsburgh office and a member of the health care group.  In her practice, Mairi regularly assists clients across the health care industry in achieving and maintaining compliance with complex regulatory schemes, including those governing licensure, patient confidentiality, and Medicare/Medicaid reimbursement.

Questions?  Please contact Kayla Allen.